Cozaar Related Published Studies
Well-designed clinical trials related to Cozaar (Losartan)
Renal and retinal effects of enalapril and losartan in type 1 diabetes. [2009.07.02]
A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension. [2009.07]
Beneficial effects of high-dose losartan in IgA nephritis. [2009.06]
Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. [2009.06]
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. [2009.06]
Effects of losartan on fibrinolytic parameters and von Willebrand factor in Chinese subjects with hypertension: a comparative study versus atenolol. [2009.05]
Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial. [2009.05]
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). [2009.04.14]
Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. [2009.04]
Efficacy of exercise, losartan, enalapril, atenolol and rilmenidine in subjects with blood pressure hyperreactivity at treadmill stress test and left ventricular hypertrophy. [2009.04]
Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. [2009.02.03]
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. [2009.01]
Comparison of therapies between fixed-dose telmisartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild to moderate hypertension. [2009.01]
Effects of allopurinol and vitamin E on renal function in patients with cardiac coronary artery bypass grafts. [2009]
Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men. [2009]
A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure. [2008.11]
Effects of early losartan therapy on ventricular late potentials in acute myocardial infarction. [2008.10]
Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. [2008.09]
Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. [2008.09]
Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor. [2008.09]
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. [2008.08]
Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. [2008.08]
Effect of Pentoxifylline in Addition to Losartan on Proteinuria and GFR in CKD: A 12-Month Randomized Trial. [2008.07.08]
Aliskiren combined with losartan in type 2 diabetes and nephropathy. [2008.06.05]
Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. [2008.06]
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. [2008.06]
Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. [2008.05]
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. [2008.05]
A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. [2008.04]
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. [2008.04]
Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. [2008.04]
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. [2008.04]
Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. [2008.04]
The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. [2008.03]
Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan. [2008.02.13]
Prevention of DNA damage in renal transplantation by losartan and enalapril: the role of renin-angiotensin system polymorphisms. [2008.02]
Effects of losartan and enalapril on high-sensitivity C-reactive protein and total antioxidant in renal transplant recipients with Renin-Angiotensin system polymorphisms. [2008.01]
Modulation of pain perception by ramipril and losartan in human volunteers. [2008.01]
The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. [2008]
Bioequivalence study of two different film-coated tablet formulations of losartan-hydrochlorothiazide in healthy volunteers. [2008]
Effect of losartan in treatment of exercise-induced myocardial ischemia. [2007.11.15]
Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. [2007.11]
Antihypertensive efficacy of amlodipine and losartan after two 'missed' doses in patients with mild to moderate essential hypertension. [2007.11]
Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. [2007.10]
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. [2007.10]
Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke. [2007.09]
Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. [2007.08]
The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. [2007.07.17]
Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. [2007.07]
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency. [2007.06]
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. [2007.05]
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. [2007.05]
Renin-angiotensin system polymorphisms and hemoglobin level in renal allografts: a comparative study between losartan and enalapril. [2007.05]
Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. [2007.03]
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. [2007.02]
Treatments with losartan or enalapril are equally sensitive to deterioration in renal function from cyclooxygenase inhibition. [2007.02]
The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. [2007.01]
Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy. [2007]
Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. [2007]
A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension. [2006.10]
Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction. [2006.08.01]
Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. [2006.08]
A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. [2006.05]
Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters. [2006.04]
Losartan improves resistance artery lesions and prevents CTGF and TGF-beta production in mild hypertensive patients. [2006.04]
A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. [2006.04]
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. [2006.03.28]
Comparative bioavailability of two losartan formulations in healthy human volunteers after a single dose administration. [2006.03]
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. [2006.03]
The effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects. [2006.03]
The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. [2006.02.23]
The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. [2006.02]
Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. [2006.02]
Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. [2006.02]
Randomized placebo-controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients. [2006.01.15]
[The "LOTHAR" study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension] [2006.01]
Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. [2006.01]
Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. [2006.01]
Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. [2006.01]
Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population. [2006.01]
Comparative bioavailability study of two ibuprofen preparations after oral administration in healthy volunteers. [2006]
Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. [2006]
Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). [2006]
Different effects of simvastatin and losartan on cytokine levels in coronary artery disease. [2006]
Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters? [2005.12]
Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension. [2005.11]
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy. [2005.11]
Comparative study of taste disturbance by losartan and perindopril in healthy volunteers. [2005.11]
Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. [2005.11]
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective. [2005.10]
Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction. [2005.10]
Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. [2005.10]
Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. [2005.10]
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. [2005.09.06]
Effects of eplerenone versus losartan in patients with low-renin hypertension. [2005.09]
Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. [2005.08.01]
Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. [2005.08]
Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function. [2005.08]
Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. [2005.07]
Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). [2005.07]
Comparative pharmacokinetics of two tablet formulations of Losartan: bioequivalence assessment. [2005.07]
|
